Kazia Therapeutics Limited
KZIA
$3.30
-$0.2395-6.77%
NASDAQ
| 06/30/2024 | 03/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 0.21% | -- | |||
| Total Other Revenue | 0.18% | -- | |||
| Total Revenue | 0.21% | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 0.21% | -- | |||
| SG&A Expenses | 0.21% | 99.51% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.21% | 150.58% | |||
| Operating Income | -0.21% | -122.40% | |||
| Income Before Tax | -0.21% | -103.75% | |||
| Income Tax Expenses | -0.22% | -0.68% | |||
| Earnings from Continuing Operations | -0.20% | -105.33% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -0.20% | -105.33% | |||
| EBIT | -0.21% | -122.40% | |||
| EBITDA | -0.21% | -136.69% | |||
| EPS Basic | -0.21% | -71.20% | |||
| Normalized Basic EPS | -0.21% | -75.84% | |||
| EPS Diluted | -0.21% | -71.20% | |||
| Normalized Diluted EPS | -0.21% | -75.84% | |||
| Average Basic Shares Outstanding | 0.00% | 19.93% | |||
| Average Diluted Shares Outstanding | 0.00% | 20.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||